Michael Birrer, MD, PhD, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.
Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More